logo

For the Inventor, By the Inventor

Milan, Italy

Francesco Lauria

USPTO Granted Patents = 17

Average Co-Inventor Count = 6.0

ph-index = 5

Forward Citations = 96(Granted Patents)


Company Filing History:

goldMedal14 out of 31 
 
Carlo Erba S.p.a.
 patents
silverMedal3 out of 181 
 
Farmitalia Carlo Erba S.p.a.
 patents

Years Active: 1977-1981

Loading Chart...
17 patents (USPTO):Explore Patents
1. 4251531 - 3,4-Dihydro-quinazoline derivatives (1981-02-17),
2. 4183946 - Substituted 2-vinyl-chromones and process for their preparation (1980-01-15),
3. 4183945 - Substituted 2-vinyl-chromones and process for their preparation (1980-01-15),
4. 4177286 - Substituted 2-vinyl-chromones and process for their preparation (1979-12-04),
5. 4177276 - Substituted 2-vinyl-chromones and process for their preparation (1979-12-04),
6. 4160028 - Substituted 2-cyclopropyl-chromones and pharmaceutical compositions and (1979-07-03),
7. 4159330 - 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and (1979-06-26),
8. 4157334 - 6-Carboxy-flavone derivatives and process for their preparation (1979-06-05),
9. 4152449 - 2-Vinyl-chromones and pharmaceuticals therewith (1979-05-01),
10. 4148900 - 5:6-Benzo-.gamma.-pyrone derivatives and process for their preparation (1979-04-10),
11. 4134974 - Imidazo[5,1-c][1,4]benzoxazin-1-one (1979-01-16),
12. 4123527 - N-tricyclic derivatives of azetidine and process for their preparation (1978-10-31),
13. 4115567 - 6-Carboxy-2-(2'-pyrazinyl)-chromones and esters thereof (1978-09-19),
14. 4083953 - Pharmaceutical composition containing 5:6-benzo-alpha-pyrone derivatives (1978-04-11),
15. 4078073 - N-tricyclic derivatives of azetidine (1978-03-07),

Title: Francesco Lauria: Innovator in Anti-Allergy Compounds

Introduction

Francesco Lauria is a prominent inventor based in Milan, Italy. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with anti-allergy properties. With a total of 17 patents to his name, Lauria's work has the potential to impact the treatment of allergic conditions.

Latest Patents

Among his latest patents, Lauria has developed 3,4-Dihydro-quinazoline derivatives. These compounds, such as 6-carboxy-2-(2'-ethoxy-phenyl)-3,4-dihydro-4-oxo-quinazoline, are disclosed for their anti-allergy properties. They can be utilized in the treatment of various allergic conditions. Additionally, he has patented substituted 2-vinyl-chromones, which exhibit anti-allergy activity. These compounds have an alkyl or alkenyl substituent at the 3-position and a styryl substituent at the 2-position, further contributing to the treatment options available for allergies.

Career Highlights

Francesco Lauria has worked with notable companies in the pharmaceutical industry, including Carlo Erba S.p.a. and Carlo Erba, S. P. A. His experience in these organizations has allowed him to refine his expertise in drug development and innovation.

Collaborations

Throughout his career, Lauria has collaborated with esteemed colleagues such as Gianfederico Doria and Maria L Corno. These partnerships have fostered a collaborative environment that enhances the research and development of new compounds.

Conclusion

Francesco Lauria's contributions to the field of anti-allergy compounds demonstrate his commitment to innovation and improving healthcare. His patents and collaborations reflect a dedication to advancing treatment options for allergic conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…